Making the case for the slower follower

By Anthony Davies

Considering the pace of the arms race for haemophilia therapies, the recently-announced collaboration between Novo and Bluebird feels quite late. Given what we know about their current progress, they’re unlikely to reach a long-term therapy first or …

Dark Horse Sponsors Phacilitate Leaders World 2019 meeting in Miami

Campbell, CA, January 21st, 2019 – Dark Horse Consulting, the leading consultancy specializing in cell and gene therapy product development, today announced its planned attendance and sponsorship of the 2019 Phacilitate Leaders World meeting, scheduled for January 22-25 in Miami, …

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.